eligibility_summary
Adults (≥18) with metastatic/recurrent BRCA1/2‑mutant tumors eligible for olaparib: breast (germline, prior chemo or, if HR+, prior/endocrine‑inappropriate) or mCRPC (germline/somatic, post anti‑androgen progression). ECOG ≤2, adequate counts, liver/renal (GFR ≥50), Hgb ≥9. Controlled HIV/HBV/HCV and treated brain mets allowed. Exclude: prior anti‑CD47, metastatic therapeutic PARPi, strong CYP3A4 use, immunosuppression, malabsorption, other trials, allergy, uncontrolled illness, pregnancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I/Ib, single-arm study (withdrawn, no subjects enrolled) of magrolimab (Hu5F9-G4) plus olaparib in metastatic/recurrent BRCA1/2-mutant breast cancer or castration-resistant prostate cancer. Magrolimab is an anti-CD47 monoclonal antibody (immunotherapy) that blocks the CD47–SIRPα “don’t‑eat‑me” signal to promote macrophage-mediated phagocytosis and innate antitumor immunity, the trial also assesses immune microenvironment changes and potential STING pathway activation. Olaparib is an oral PARP1/2 inhibitor (targeted therapy) that impairs DNA repair, exploiting homologous recombination deficiency in BRCA1/2-mutant tumors to induce lethal DNA damage. Cells/pathways targeted: tumor CD47/SIRPα axis, macrophages/innate immunity, STING pathway, and DNA damage response/homologous recombination (HR/DDR). Primary: safety (DLTs/MTD/P2RD), secondary: PK, HR/DDR status. Magrolimab IV, olaparib PO BID.